Endermologie Versus Negative Pressure Therapy on Postmastectomy Lymphedema

NCT ID: NCT05761353

Last Updated: 2023-12-27

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

68 participants

Study Classification

INTERVENTIONAL

Study Start Date

2022-06-29

Study Completion Date

2023-10-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Statement of the problem:

The problem will be stated in a questionary form:

"Which will be more effective endermologie or negative pressure therapy in reducing limb circumference and volume in postmastectomy lymphedema?".

Hypothesis:

It will be hypothesized that:

There is no significant difference between endermologie and negative pressure therapy in reducing circumference and limb volume in post mastectomy lymphedema.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Subject:

Sixty- eight women treated for unilateral breast cancer with secondary upper limb lymphedema post mastectomy will participate in this study. Their ages will be ranged from 40 to 60 years, they will be free from any other diseases that will affect or influence the results and the participants will be selected from National Cancer Institute and randomly distributed into two equal groups in number.

Study design:

In this study the patients will be randomly assigned into two groups equal in number (34 patients for each group).

Inclusion Criteria:

The subject selection will be according to the following criteria:

* Only females will participate in the study.
* Patients' age will be ranged between 40-60 years.
* All patients will suffer from post mastectomy lymph-edema.
* All patients have a modified radical mastectomy.
* All patients will suffer from grade II lymph edema without skin changes one year post mastectomy.
* All patients are right-dominant hand.
* All patients enrolled to the study have their informed consent.

Exclusion Criteria:

The potential participants will be excluded if they meet one of the following criteria:

* primary lymph-edema.
* Diabetes mellitus.
* Pregnancy.
* Recurrent cancer.
* Current or recent cellulitis.
* Current metastases.
* Venous thrombosis.
* Photosensitivity.
* Phlebitis in development stage.
* Infection.
* Receiving anti-coagulant treatment.

Equipment:

The study equipment's will be divided into measurement and therapeutic equipment and tools:

1: Measurement equipment

1(a):Limb volume measurement:

This will be performed by measuring the circumference of each segment of the limb between two consecutive circumferences as a truncated zone. The volume of the segment was calculated as:

V=h (c12+c1c2+c22 )/12π, where V is the volume of the segment, c1 and c2 are the circumferences at the ends of the segment, and h is the distance between them.

Measurement of limb volume measurement will be conducted pre-treatment and after treatment course (6 weeks).

1. (b): Measuring Disability of the arm, shoulder and hand by: .Quick DASH questionnaire (Disability of the arm, shoulder, and hand).

* The Quick- DASH has five response options for each item from 0=no difficulty to perform or no symptoms to 5=unable to do.
* Quick DASH scale will be conducted pre-treatment and after treatment course (6 weeks).
2. Therapeutic equipment :

2\. a. Endermologie: endermologie therapy will be three sessions per week for six weeks (total 18 sessions).

The study group will receive 18 sessions by Endermologie system ( used to decrease postmastectomy lymphedema for group (A), three sessions per week for six weeks.

Each session was 30 minutes at the posterior thorax, upper arm, forearm and the hand.

2.b. Negative pressure therapy:

* Pressure: 20-250 mm Hg.
* Total treatment period: six weeks.
* A number of sessions: 3 sessions/ week. Time of application : 30 min

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Mastectomy; Lymphedema

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Group A (endermologie group)

This group includes 34 patients who will receive 30 min Endermologie 3 times per week in addition to their physical therapy program (active range of motion and elevation); hygiene and skin care for 6 weeks.

Group Type EXPERIMENTAL

Endermologie

Intervention Type DEVICE

Group A will receive -18 sessions by Endermologie system used to decrease postmastectomy lymphedema for group (A), three sessions per week for six weeks.

Each session was 30 minutes at the posterior thorax, upper arm, forearm and the hand.

-In addition to physical therapy program (active range of motion and elevation); hygiene and skin care

Group B (Negative pressure therapy group)

This group includes34 patients who will receive 30min negative pressure therapy 3 times per week in addition to their physical therapy program (active range of motion and elevation); hygiene and skin care for 6 weeks

Group Type EXPERIMENTAL

Negative pressure therapy

Intervention Type DEVICE

Group B will receive negative pressure therapy with

* Pressure: 20-250 mmHg.
* Total treatment period: 6weeks
* A number of sessions: 3sessions/ week. Time of application : 30 min
* In addition to physical therapy program (active range of motion and elevation); hygiene and skin care

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Endermologie

Group A will receive -18 sessions by Endermologie system used to decrease postmastectomy lymphedema for group (A), three sessions per week for six weeks.

Each session was 30 minutes at the posterior thorax, upper arm, forearm and the hand.

-In addition to physical therapy program (active range of motion and elevation); hygiene and skin care

Intervention Type DEVICE

Negative pressure therapy

Group B will receive negative pressure therapy with

* Pressure: 20-250 mmHg.
* Total treatment period: 6weeks
* A number of sessions: 3sessions/ week. Time of application : 30 min
* In addition to physical therapy program (active range of motion and elevation); hygiene and skin care

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Only females will participate in the study.
* Patients' age was ranged between 40-60 years.
* All patients will suffer from post mastectomy lymphedema.
* All patients have a modified radical mastectomy.
* All patients suffer from grade II lymphedema without skin changes one year post mastectomy(as defined by the International Society of Lymphology).
* All patients are right-dominant hand.
* All patients enrolled to the study will have their informed consent.

Exclusion Criteria

* The potential participants will be excluded if they meet one of the following criteria:

* primary lymphedema.
* Diabetes mellitus.
* Pregnancy.
* Recurrent cancer.
* Current or recent cellulitis.
* Current metastases.
* Venous thrombosis.
* Photosensitivity.
* Phlebitis in development stage.
* Infection.
* Receiving anti-coagulant treatment.
Minimum Eligible Age

40 Years

Maximum Eligible Age

60 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Cairo University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Rayda Maher Mohamed Abdelkhalek

assistant lecturer

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Rayda M Mohamed

Role: PRINCIPAL_INVESTIGATOR

Cairo Unversity

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Outpatient clinic, Faculty of Physical Therapy, Cairo university

Giza, Dokki, Egypt

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Egypt

Provided Documents

Download supplemental materials such as informed consent forms, study protocols, or participant manuals.

Document Type: Statistical Analysis Plan

View Document

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

P.T.REC/012/003744

Identifier Type: -

Identifier Source: org_study_id